- Home
- / PetMed Express
PetMed Express
Average Spending per Transaction
$85
Q2, 2018
Revenue
$273.4 M
FY, 2022
Market Capitalization
$403.2 M
2022-11-18
PetMed Express Summary
Company summary
- Overview
- PetMed Express markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. The Company's products include brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution and Rimadyl. PetMed also offers additional pet supplies for sale on its Website, which are drop shipped to its customers by third parties.
- Type
- Public
- Status
- Active
- Founded
- 1996
- HQ
- Delray Beach, FL, US | view all locations
- Website
- http://www.1800petmeds.com/
- Cybersecurity rating
- ESG rating
Operating MetricsView all
Stock Keeping Units
3K
FY, 2017
Visitors
32M
3.0%
FY, 2017
Average Spending per Transaction
$85
3.7%
Q2, 2018
PetMed Express Financials
Summary financials
- Revenue (Q2, 2023)
- $65.4M
- Gross profit (Q2, 2023)
- $18.5M
- Net income (Q2, 2023)
- $2.6M
- Cash (Q2, 2023)
- $96.5M
- EBIT (Q2, 2023)
- $3.0M
